Clinical trials: PDAC - Pancreatic Ductal Adenocarcinoma
Neoplasms Pancreatic
PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer
PRIMUS 002 is looking at 2 different chemotherapy regimens in the neo-adjuvant setting for pancreatic cancer. Each treatment will be given for 3 months prior to surgery
- Trial name
- PRIMUS002 (NCT04176952)
- Testing
- FOLFOX-A, AG
- Where
- 3 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Judith Dixon-Hughes
Pancreatic Ductal Adenocarcinoma
Differentiating Tumor-stroma Ratio in Pancreatic Ductal Adenocarcinoma
This study introduces a novel transfer learning-based contrastive language-image pretraining adapter (CLIP-adapter) model for predicting the tumor-stroma ratio (TSR) in pancreatic ductal adenocarcinoma (PDAC) using preoperative…
- Trial name
- NCT06302881
- Volunteers
- 207 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Neoplasms Pancreatic
A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma
The AJCC TNM staging system is the prevailing method in prognostic evaluation of pancreatic ductal adenocarcinoma (PDAC) at present , but it did not include factors such as the tumor immune microenvironment that are known to…
- Trial name
- NCT05547074
- Testing
- pancreatic cancer surgery
- Where
- China
- Volunteers
- 302 people
- Sponsor
- Zhejiang University
Pancreatic Ductal Adenocarcinoma, Surgery
Comparing Total Laparoscopic Versus Open Pancreaticoduodenectomy
Introduction Pancreatoduodenectomy (PD) is one of the most complex abdominal operations to perform, and it is usually conducted for tumours of the periampullary region and chronic pancreatitis.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Surgery, Periampullary Cancer
- Trial name
- NCT03138213
- Testing
- Total laparoscopic pancreaticoduodenectomy, Open pancreaticoduodenectomy
- Where
- China
- Volunteers
- 656 people
- Sponsor
- Tongji Hospital
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer
A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups
PanFAM-1 is a clinical study for early detection of pancreatic cancer in high-risk groups. The goals of the study are to assess the performance and diagnostic accuracy of the IMMray™ PanCan-d test compared to standard-of-care…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome
- Trial name
- NCT03693378
- Where
- 21 sites in United States, Canada and 3 more
- Volunteers
- 1,349 people, healthy volunteers welcome
- Sponsor
- Immunovia, Inc.
Adenocarcinoma of the Pancreas
Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma
This is a clinical trial that tests a surgical treatment. Everyone in the study will get the same treatment, and there is no comparison or placebo group.
- Trial name
- PHOLIPANC (NCT07340151)
- Testing
- Surgical resection
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Pancreatic Cancer Recurrence in the Netherlands
The aim of this nationwide, observational cohort study is to evaluate current surveillance strategies after primary resection of pancreatic ductal adenocarcinoma (PDAC) in the Netherlands, with regard to the detection, treatment…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer, PDAC
- Trial name
- NCT04605237
- Where
- Netherlands
- Volunteers
- 1,750 people
- Sponsor
- UMC Utrecht
Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy
The Impact of Hepatic Steatosis on Survival After Pancreaticoduodenectomy
We will use simple summaries, educational handouts, and discussions with doctors and nurses to explain this study. The study looks at patients with early-stage pancreatic cancer who undergo pancreaticoduodenectomy (Whipple…
- Trial name
- NCT07182136
- Testing
- Pancreaticoduodenectomy
- Volunteers
- 200 people
- Sponsor
- Wei-Hsun Lu
Pancreatic Cancer, Ampullary Cancer
Recurrence After Whipple's (RAW) Study
Pancreatic head malignancies are aggressive cancers that are often inoperable when they are diagnosed. In the ~20% of patients who are diagnosed when the disease is still operable, surgery is the only treatment that can provide a…
- Conditions
- Pancreatic Cancer, Ampullary Cancer, Bile Duct Cancer, Cholangiocarcinoma, Extrahepatic
- Trial name
- NCT04596865
- Testing
- Pancreaticoduodenectomy
- Where
- 29 sites in Australia, Austria and 6 more
- Volunteers
- 1,484 people
- Sponsor
- University Hospital Plymouth NHS Trust
Pancreas Cancer
Pancreaticoduodenectomy in Elderly Pancreatic Ductal Adenocarcinoma Patients
We used the SEER database to analyze the data of patients with PDAC. The database includes patients of 18 registries in the USA from 1973-2013All the malignant cases were followed-up annually to determine vital status.
- Trial name
- NCT03659903
- Testing
- pancreaticoduodenectomy
- Volunteers
- 5,910 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
Autoimmune Pancreatitis
CT Findings in Surgically Treated Focal Pancreatic Disease- A Retrospective Study
To retrospectively investigate CT imaging features of autoimmune and chronic pancreatitis (AIP and CP) mimicking pancreatic ductal adenocarcinoma in surgically resected patients.
- Trial name
- NCT06699667
- Testing
- Computed tomography
- Volunteers
- 41 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Pancreatic Ductal Adenocarcinoma
Radiomics Based on Multimodal Imaging in Predicting Staging and Prognosis of Pancreatic Cancer
Retrospectively analyzed radiomics features of pancreatic ductal adenocarcinoma to predict staging and prognosis
- Trial name
- NCT04954378
- Testing
- radiomics
- Volunteers
- 300 people
- Sponsor
- Peking University Third Hospital
Neuroendocrine Tumor of Pancreas, Carcinoma, Pancreatic
Related Studies of Imaging Features and Prognosis Between Pancreatic Neuroendocrine Tumors and Pancreatic Cancer
1. Imaging findings (including CT and MRI images) of both well-differentiated G3 PNET and poorly differentiated PNET were studied; 2.
- Conditions
- Neuroendocrine Tumor of Pancreas, Carcinoma, Pancreatic, CT
- Trial name
- NCT04977596
- Testing
- No intervention
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colorectal Carcinoma, Endometrial Carcinoma
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory).
- Conditions
- Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma
- Trial name
- NCT04851119
- Testing
- Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint
- Where
- 21 sites in United States
- Volunteers
- 147 people
- Sponsor
- Children's Oncology Group
Pancreatic Neoplasm, Pancreas Cancer
MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer
Developing a characteristic ctDNA methylation panel for pancreatic ductal adenocarcinoma and establishing an intelligent diagnostic and dynamic monitoring model based on ctDNA methylation.
- Trial name
- NCT07045571
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Yingbin Liu, MD, PhD, FACS
Pancreatic Ductal Adenocarcinoma
Study of the Effect of Prehabilitation on Markers of Sarcopenia in Patients Undergoing Pancreatoduodenectomy for Malignant Disease
The aim of this study is to assess whether prehabilitation supervised by an appropriate multimodality team improves indices of sarcopenia in patients scheduled to undergo pancreatoduodenectomy.
- Trial name
- SIPUP (NCT03770117)
- Testing
- Prehabilitation, Standard Procedure
- Where
- United Kingdom
- Volunteers
- 113 people
- Sponsor
- Manchester University NHS Foundation Trust
Pancreatic Adenocarcinoma
Immunohistochemical Expression of PD-L1 in Pancreatic Ductal Adenocarcinoma
Pancreatic carcinoma is ranked the 11th most common cancer worldwide. It is a highly lethal malignant tumor. In Egypt, the disease has traditionally been considered rare, but population in the East Nile Delta region exhibits an…
- Trial name
- NCT05228808
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Advanced Solid Tumors
TT-702 in Patients With Advanced Solid Tumours.
This clinical trial is evaluating the drug candidate TT-702 in patients with advanced solid tumours. The main aims of the trial are to determine the maximum dose of TT-702 that can be given safely to patients alone and in…
- Trial name
- CURATE (NCT05272709)
- Testing
- TT-702, Anti-PD-1 and PD-L1 agent
- Where
- 3 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Cancer Research UK
Pancreatic Ductal Adenocarcinoma
Survival Among Patients With Pancreatic Cancer Depending on Surgical Resection Rate
The primary aim of this population-based study is to investigate how a high resection rate of pancreaticoduodenectomy affects overall survival among patients aged ≥70 years with pancreatic ductal adenocarcinoma.
- Trial name
- NCT04802993
- Testing
- Resection rates
- Volunteers
- 5,123 people
- Sponsor
- Linkoeping University